Affiliation: University of Michigan
- Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancerVered Stearns
Breast Cancer Program, Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
Ann Surg Oncol 9:235-42. 2002..Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy...
- Approach to menopausal symptoms in women with breast cancerVered Stearns
The Breast Cancer Program, University of Michigan Comprehensive Cancer Center, 6303 Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0942, USA
Curr Treat Options Oncol 3:179-90. 2002..Selective serotonin re-uptake inhibitors should be considered as a first-line nonhormonal pharmacologic therapy for women with menopausal symptoms...
- Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancerN Lynn Henry
University of MichiganComprehensive Cancer Center, Ann Arbor, MI, USA
J Clin Oncol 30:936-42. 2012..Predictors of treatment discontinuation are not clearly defined. It is unknown whether patients with intolerable toxicity from one AI are able to tolerate another...
- Drug interactions and pharmacogenomics in the treatment of breast cancer and depressionN Lynn Henry
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 300 North Ingalls St, Bldg. 3A04, Ann Arbor, MI 48109-5419, USA
Am J Psychiatry 165:1251-5. 2008
- CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJames M Rae
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
J Natl Cancer Inst 104:452-60. 2012..Previous studies have suggested that metabolic conversion of tamoxifen to endoxifen by cytochrome P450 2D6 (CYP2D6) is required for patient benefit from tamoxifen therapy...
- Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trialVered Stearns
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
J Clin Oncol 23:6919-30. 2005..A secondary objective was to evaluate quality of life (QOL) parameters...
- Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancerAditya Bardia
Breast Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building 1, Room 144, 1650 Orleans Street, Baltimore, MD 21231, USA
Breast Cancer Res Treat 131:907-14. 2012..Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD...
- Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortN Lynn Henry
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
Breast Cancer Res Treat 117:571-5. 2009..062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy...
- A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonographyN Lynn Henry
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5419, USA
Cancer 116:4360-7. 2010..Tendon sheath fluid and tenosynovial changes have been demonstrated by imaging symptomatic patients who were treated with AIs. The authors hypothesized that these abnormalities are correlated with AIMSS...
- Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for managementStephanie Gaillard
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA
Breast Cancer Res 13:205. 2011..Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes...
- A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activityVered Stearns
Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
Clin Cancer Res 10:8332-40. 2004..We chose tamoxifen to establish proof of principal with a known effective agent...
- Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumorsYong Soon Chun
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Breast Cancer Res Treat 135:201-8. 2012..Unless there are fundamental species differences in PLD metabolism in rodents and humans, this finding seriously limits the consideration of i.duc PLD use in the clinic for treatment or prevention of breast cancer...
- CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevanceMichaela J Higgins
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 145, Baltimore, MD 21231, USA
Curr Oncol Rep 12:7-15. 2010..This review summarizes the literature to date with a focus on clinically relevant recent studies that examined the association between CYP2D6 polymorphisms and tamoxifen-associated outcomes...
- Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for managementN Lynn Henry
Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, Michigan 48109 5419, USA
Oncology (Williston Park) 22:1401-8. 2008..Increased knowledge about the etiology and management of this clinically important toxicity could potentially improve patient adherence to AI therapy, thereby leading to a reduction in breast cancer recurrence and death...
- Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetineVered Stearns
The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
J Natl Cancer Inst 95:1758-64. 2003..Coadministration of paroxetine decreased the plasma concentration of endoxifen. Our data suggest that CYP2D6 genotype and drug interactions should be considered in women treated with tamoxifen...
- Management of hot flashes in breast cancer survivors and men with prostate cancerVered Stearns
Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M53, Baltimore, MD 21231 1000, USA
Curr Oncol Rep 6:285-90. 2004..However, such hormonal therapies as depomedroxyprogesterone acetate can be prescribed for an informed individual who experiences bothersome symptoms despite nonhormonal treatments...
- Preclinical and clinical evaluation of intraductally administered agents in early breast cancerVered Stearns
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Sci Transl Med 3:106ra108. 2011..If successful, administration of agents directly into the ductal system may allow for "breast-sparing mastectomy" in select women...
- Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinantsVered Stearns
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Nat Rev Cancer 6:886-93. 2006..Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions...
- A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasiaVered Stearns
Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C, USA
Clin Cancer Res 10:7583-91. 2004..Further investigations must overcome logistical obstacles to accrual, and they must focus on approaches to maximize tissue collection and to incorporate genomic analysis of target lesions...
- Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trialVered Stearns
Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
JAMA 289:2827-34. 2003..Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective...
- More choices, more questions: weighing the options for treating hot flashesVered Stearns
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231-1000, USA
J Support Oncol 4:323-5. 2006
- Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens
Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Clin Oncol 27:5911-8. 2009..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
- Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitorsN Lynn Henry
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0942, USA
Breast Cancer Res Treat 111:365-72. 2008..AIs are commonly associated with musculoskeletal symptoms. The primary objective of this study was to describe the musculoskeletal symptoms that developed in the first 100 subjects enrolled who had at least 6 months follow-up...
- Epigenetic regulation as a new target for breast cancer therapyVered Stearns
Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
Cancer Invest 25:659-65. 2007
- A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancerVered Stearns
Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
Clin Cancer Res 9:124-33. 2003....
- Hot flushesVered Stearns
Breast Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Georgetown, USA
Lancet 360:1851-61. 2002..Moreover, the efficacy of these drugs provides new insight into the pathophysiology of hot flushes. In this critical review, we assess knowledge of the epidemiology, pathophysiology, and treatment of hot flushes...
- Extended adjuvant therapy for breast cancer--how much is enough?Tatiana M Prowell
J Natl Cancer Inst 99:1825-7. 2007
- A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?Daniel F Hayes
J Natl Cancer Inst 100:610-3. 2008
- Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivorsGary Elkins
Department of Psychology and Neuroscience, Baylor University, Waco, TX 76798, USA
J Clin Oncol 26:5022-6. 2008..A well-tolerated and effective mind-body treatment for hot flashes would be of great value. On the basis of previous case studies, this study was developed to evaluate the effect of a hypnosis intervention for hot flashes...
- Cooling off hot flashesVered Stearns
J Clin Oncol 20:1436-8. 2002
- Clinical update: new treatments for hot flushesVered Stearns
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
Lancet 369:2062-4. 2007
- CYP2D6 genotype and tamoxifen responseJames M Rae
Breast Cancer Res 7:E6. 2005
- Centrally active nonhormonal hot flash therapiesCharles L Loprinzi
Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
Am J Med 118:118-23. 2005..The most efficacious and clinically appropriate agents for use are newer antidepressants and gabapentin. Continued evaluation of the efficacy and toxicity of these agents is ongoing...
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an updateManfred Kaufmann
Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
J Clin Oncol 24:1940-9. 2006..As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined...
- CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatmentYan Jin
Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
J Natl Cancer Inst 97:30-9. 2005....
- Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim supportAntonio C Wolff
J Clin Oncol 24:2392-4; author reply 2394-5. 2006
- Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CTHeather A Jacene
Division of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Clin Nucl Med 31:379-81. 2006..This case highlights the importance of clinical history and laboratory correlation for the proper interpretation of FDG PET scans...
- Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatmentSilvana Borges
Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
Clin Pharmacol Ther 80:61-74. 2006..We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations...
- Can hypnosis reduce hot flashes in breast cancer survivors? A literature reviewGary Elkins
Scott and White Hospital and Clinic, Temple, TX 76508, USA
Am J Clin Hypn 47:29-42. 2004..However this intervention has not been adequately studied. We discuss an NIH-funded randomized clinical trial of hypnosis for hot flashes in breast cancer survivors that is presently being conducted...
- New therapeutic approaches for hot flashes in womenVered Stearns
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231 1000, USA
J Support Oncol 1:11-21; discussion 14-5, 19-21. 2003..We will focus on nonhormonal treatments that have been studied in prospective randomized clinical trials, and will present an algorithm for the treatment of symptomatic patients...
- Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyondTing Bao
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231-1000, USA
Am J Ther 13:337-48. 2006....
- Déjà vu for breast cancer two?Vered Stearns
J Natl Cancer Inst 96:497-9. 2004
- Role of CYP2D6 testing in selection of endocrine therapy for breast cancerJustin Stebbing
Pharmacogenomics 8:1-3. 2007
- Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applicationsMichael A Jacobs
The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Technol Cancer Res Treat 3:543-50. 2004..A combination of MR, MRSI, and 23Na sodium MR parameters may be examined in a single MR imaging examination, potentially resulting in improved specificity for radiologic evaluation of malignancy...
- Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRIRonald Ouwerkerk
Division of MR Research, Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21287 0845, USA
Breast Cancer Res Treat 106:151-60. 2007....
- Lipophilic statins merit additional study for breast cancer chemopreventionTatiana M Prowell
J Clin Oncol 24:2128-9; author reply 2129. 2006
- Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studiesHeather A Jacene
Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA
J Nucl Med 47:950-6. 2006..These profound alterations in (18)F-FDG biodistribution induced by pegfilgrastim must be considered when one is evaluating quantitative (18)F-FDG PET scans for tumor response to therapy...
- Adjuvant aromatase inhibitors and emerging quality-of-life considerationsSusanne Briest
Expert Rev Anticancer Ther 8:1-4. 2008
- Chemotherapeutic Strategies for advanced breast cancerSusanne Briest
University of Leipzig Department of Gynecology and Obstetrics Leipzig, Germany
Oncology (Williston Park) 21:1325-35; discussion 1338, 1340. 2007..In this review, we will provide an update on commonly used chemotherapy-based regimens for the treatment of metastatic breast cancer, with a focus on tailoring therapy to different subtypes of the disease...
- Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivorsGary Elkins
Mind Body Cancer Research Program, Scott and White Memorial Hospital, Temple, TX, USA
Psychooncology 16:487-92. 2007..A randomized, controlled clinical trial is planned to more definitively elucidate the efficacy and applicability of hypnosis for reducing hot flashes...
- A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicinLeisha A Emens
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231-2410, USA
Hum Gene Ther 15:313-37. 2004